{{Rsnum
|rsid=619824
|Chromosome=10
|position=104581288
|Orientation=minus
|GMAF=0.4812
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=132
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}
{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 37.2 | 40.7 | 22.1
| HCB | 17.5 | 47.4 | 35.0
| JPT | 27.4 | 51.3 | 21.2
| YRI | 12.2 | 44.9 | 42.9
| ASW | 7.0 | 49.1 | 43.9
| CHB | 17.5 | 47.4 | 35.0
| CHD | 14.7 | 53.2 | 32.1
| GIH | 25.7 | 51.5 | 22.8
| LWK | 10.9 | 33.6 | 55.5
| MEX | 32.8 | 51.7 | 15.5
| MKK | 19.9 | 44.9 | 35.3
| TSI | 31.4 | 52.9 | 15.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=21791469
|Title=Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
|OA=1
}}

{{PMID|16782804|OA=1
}} Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.

{{PMID|19015200|OA=1
}} Polymorphisms in estrogen- and androgen-metabolizing genes and the risk of gastric cancer.

{{PMID|20411041|OA=1
}} Common Variation in the CYP17A1 and IFIT1 Genes on Chromosome 10 Does Not Contribute to the Risk of Endometriosis.

{{PMID|21229561}} CYP17 gene polymorphisms and prostate cancer risk: A meta-analysis based on 38 independent studies.

{{PMID|21656827}} CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.

{{PMID Auto
|PMID=23015357
|Title=Menstrual and reproductive factors in women, genetic variation in CYP17A1, and pancreatic cancer risk in the European prospective investigation into cancer and nutrition (EPIC) cohort.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}